Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2
作者:Kazuki Fujimoto、Eriko Matsuoka、Naoya Asada、Genta Tadano、Takahiko Yamamoto、Kenji Nakahara、Kouki Fuchino、Hisanori Ito、Naoki Kanegawa、Diederik Moechars、Harrie J. M. Gijsen、Ken-ichi Kusakabe
DOI:10.1021/acs.jmedchem.9b00309
日期:2019.5.23
inhibitors using structure-based drug design. We targeted the flap region, where the shape and flexibility differ between these enzymes. Analysis of the cocrystal structures of an initial lead 8 prompted us to incorporate spirocycles followed by its fine-tuning, culminating in highly selective compounds 21 and 22. The structures of 22 bound to BACE1 and BACE2 revealed that a relatively high energetic penalty
BACE1抑制剂在阿尔茨海默氏病的疾病改良治疗中具有潜在的作用。BACE2在皮肤和眼睛的色素细胞中裂解黑色素细胞蛋白PMEL,生成黑色素色素。BACE2的这种作用意味着对BACE1的非选择性和长期抑制可能导致源自BACE2的副作用。在本文中,我们描述了使用基于结构的药物设计发现有效和选择性BACE1抑制剂的过程。我们针对的是皮瓣区域,这些酶之间的形状和柔韧性不同。对初始铅8的共晶结构的分析促使我们引入螺环,然后对其进行微调,最终形成高度选择性的化合物21和22。与BACE1和BACE2结合的22的结构表明,在22结合的BACE2结构的瓣中较高的能量损失可能会导致BACE2效能的损失,从而导致其高选择性。这些发现和见解应有助于应对探索选择性BACE1抑制剂的挑战。